Thank you very much. I'm Simon Østergaard, President and CEO of the company, and I have Magnus Blix, our CFO, with me today. We appreciate you tuning in during this summer season to hear about our Q2 results and our performance halfway through 2024. We are pleased to share the outcomes with you. Let's just jump right into it.
So, what do we call the quarter in brief? We achieved 11% growth in the quarter. Organically, that was 10%. This had hardly any impact on our results of $188 million in revenues. The EBITDA for the quarter was $60 million. That corresponds to an EBITDA margin of 32%.
We exceeded our financial ambition by achieving over 30% in EBITDA. I'd say the highlights of the quarter were stability, albeit with some fluctuations. Top-level, we were very pleased with what we have seen in APAC across multiple countries. We see consistent performance out of the EMEA region.
This quarter, we observed a temporary slowdown in the Americas. Regarding our strategic pillars, we have successfully completed internal preclinical studies for our bone marrow applications. We're now ready to proceed with external clinical validation throughout the autumn. This is an exciting phase for us.
We have invested a significant amount of effort in interacting with new Sysmex colleagues across regional organizations to implement and adopt the Strategic Alliance Agreement that we signed with Sysmex in early February this year. All right. Let me delve deeper into the numbers. I know this format is busy, but it remains very informative. Here we have all the comparisons we need. We talked about the DIFF-Line and so on.
On the very left-hand side, you see the new numbers we report today. In the middle column, we have the year-to-date figures for the year. We are now at $188 million for this quarter. Which brings us to $358 million, so far this half-year. This represents an organic growth of 16% year-to-date. For the gross margin, we are also reporting 66% this quarter. Um, that's a little bit low given the levers around product mix. We also have had increased material and product costs throughout the year. However, we have not seen a significant effect on the price increases that we implemented this year. So we should see them influence our gross margin when we get to Q3 operating expenses. Um, we have spent 75 million versus 73 million in the comparable quarter of last year.
So I think we've been very successful in maintaining our cost base and sales despite some inflationary increases. That is due to some restructuring we did last autumn. Uh, the full impact of that on the admin, we are also pretty much in control, albeit increasing slightly. We are building a muscle for some of the regulatory requirements and therefore spending more. So here we are spending a bit more on consultants to be prepared and build support for our business in R&D.
Um, it goes a little bit down. We are capitalizing more, from 14 million to 16 million this quarter. Uh, so that is really a sign of the maturity in our development programs. So that's good to see. Um, I mentioned the EBITDA of 60 million, which translates into a 32% margin. So, despite the somewhat lower gross margin, we still have a healthy EBITDA margin of 32%.
Um, and cash flow wise, we had a cash flow, um, before adjustment for working capital of 54 million. So, given the overall, it's a good quarter, a solid quarter as we say. Um, however, given the growth we have, then we have some outstanding accounts receivable. And that brings our operating cash flow down to 40 million. And then if we deduct the investment activities, especially capitalized R&D of 16 million, but also other financial activities,
That influences the cash flow. Then we have both dividend payouts of 54 million, And we also have the amortization and leasing of around 11 million. So that brings us down to a total cash flow of -44 million. So that's really, uh, a brief run through.
Excuse me. Uh that's it. That's a brief run through of the personnel. Let's try and just give a bit of regional highlights. Mhm. So, as I said, on the top-line side, a little low or soft in the Americas. Um, and that is primarily on the large instrument site. So here we did have some operational matters that actually impacted the installation pace.
There has been a bit of a drag in the Americas this quarter. We don't believe it's systemic with regards to market demand. We have seen continued interest and double-digit growth in our small instruments, and that is an interest that spans across the entire Americas. This is still super promising and really emphasizes the opportunities we have to serve the networks in that part of the world, but also in South America.
In fact, looking at India, sales increased to $83 million versus $76 million, marking another quarter of growth in the Americas. This is promising, showing 10% growth this quarter and 15% year over year. It's really good to see how we have started to work and establish joint action plans across multiple markets. We are getting a better understanding and supporting how we leverage our system and materials to really convert and adopt digital cell morphology across this region. We also received very positive feedback from our participation at the ESL show in France, in May.<>br />
> That was rewarding and also very motivating for us, giving first-hand customer feedback on some of the innovation projects we're working on in APAC. In fact, it was pretty much a record high. We saw a 198% growth, achieving $37 million versus $13 million. That's obviously a very high growth number. Again, it fluctuates quite a bit in that region, because we are very dependent on when we ship to that part of the world where we sometimes ship quite a lot of instruments, and sometimes there are hardly any for certain jurisdictions.
What I'm very pleased about with this number is that it's spread across multiple jurisdictions. We're seeing a comeback on track in Japan. We’ve been suffering. We had a year with inventory issues in Japan. But we are out of the woods now.
There's a healthy demand from Japan and from China again. We are actually also starting to see some really interesting developments in Australia. This is not just a high revenue number, but it's also a very positive outlook. Also, given the more collaborative approach that we are starting to implement with our distribution partners and distribution across that region, if we analyze the numbers per product group as shown here. Again, there was 16% growth on the instrument side altogether, totaling $107 million.
This is a significant increase from the comparable period. We take the six-month period to be $199 million versus $158 million. That's a healthy number. Again, I see instrument sales in APAC. As I just mentioned, but I would also highlight this line, which includes our smear box, the stain box, and the DC one that are gaining a lot of traction and attention in Canada and Latin America. So here we are, really working on getting ready for that and having the registrations there. The pre-marketing and the conversations with the labs are ongoing. And that seems to really resonate. The value proposition of this DIFF-Line really resonates with the labs in those markets. On the reagent side, 1%. It's a bit soft, at face value. So it's definitely lower than when we take it quarter by quarter. It is lower than usual, I think. Here, actually, our full year or year to date, Sorry, our year to date number of 10%, really demonstrates that we had a strong Q1. So there's a little bit of facing here. But, I also want to say that our compare here is actually relatively high. When we talk about growth, we also had some production issues last year, which meant that we shipped quite a bit in Q2. So the comparison is also a little bit tough against us in this very quarter. And still, momentum across the business. We are really pushing out the reagents, especially hematology reagents, where we see growth across India. We are starting to also get the benefits of the capacity expansion that we implemented with the new factory completed at the end of last calendar year. On the software side, we increased a few million to 44 million versus the compare. Here I think the highlight is definitely that we are starting to see not only the EMEA growth in general, but the software sales are picking up. It's really good. It is a sign of them also adopting our remote review. And that is very healthy. I think that is probably the relevant comment for that.
To summarize, the key takeaways point to what we define as a solid quarter. But of course, in this business, as it's not a consumable business, We do have some soft aspects here that we actually don't believe are systemic. But we definitely saw the appetite and the orders coming from APAC as a highlight and as a positive sign. We saw a bit of a slowdown in the installation pace in the Americas that we believe will be recovered. Again, very good to see the software in the medium. Good progress. Today, I chose to report a little on the bone marrow as just to follow through, given our previous communication that we expect to commercialize our bone marrow molecule during 2025, which is the plan we are pursuing.
And then again, the collaborative efforts with Sysmex in particular are really progressing. And I really highly appreciate the way we've started to work at multiple levels within the organizations. So that also gives a very energizing impact within our organization here at Celebration. With that, I will open for questions.